Orthobond Secures $8.3M Debt Financing for Antimicrobial Surface Technology

Orthobond Raises $8.3 Million in Debt Financing

Orthobond, a New Jersey-based surface-technology company, has raised $8.3 million in a debt financing round, as announced on September 1, 2026. The funding will support the company's efforts to commercialize its proprietary antimicrobial nanosurfaces.

Technology Overview

Orthobond develops covalently bound antimicrobial nanosurfaces that kill bacteria, viruses, and fungi mechanically—without relying on antibiotics or eluting chemicals. This technology is designed for medical devices and has potential applications in commercial, industrial, and automotive sectors.

Lead Product: OSTAGUARD

The company's lead product, OSTAGUARD, is an antibacterial coating for implantable devices. It received FDA De Novo clearance in 2024, making it the first non-drug-eluting antibacterial implant surface treatment. The initial application is in spinal implants, and Orthobond delivered its first commercial OSTAGUARD-coated implants in January 2025.

Partnerships and Prior Investment

Orthobond reports partnerships across orthopedics, plastic surgery reconstruction, ophthalmology, ENT, and dental fields. In 2024, Kineticos Life Sciences' AMR Accelerator Fund I invested in the company to support commercialization of the technology.

Use of Funds

The company will use the new debt financing to further its commercialization efforts and expand the reach of its antimicrobial surface technology. Specific details on allocation were not provided.

Outlook

With this additional capital, Orthobond aims to build on its regulatory milestones and industry partnerships to bring its innovative surface treatments to a broader market.